Phase 3 N=20 Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance
Heart Failure
Primary: Change in Body Weight — -1.9; -1.9 kilogram
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=251 Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Moderate-to-Severe Atopic Dermatitis · Dermatitis, Dermatitis Atopic · Eczema, Skin Diseases, Skin
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction From Baseline of ≥2 Points) at Week 16 — 2.4; 17.9; 24.4 Percentage of…
Phase 3 N=12 An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study
Solid Tumor
Primary: Percentage of Participants With Serious Adverse Events Considered Related to Onartuzumab — 0 Percent
Phase 3 N=1,552 Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles
Contraception
Primary: Number of Pregnancies (Evaluable Cycles) — 2.9 Pearl Index
Phase 3 N=101 Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.
Diagnosis of Adult Growth Hormone Deficiency (AGDH)
Primary: Receiver Operating Characteristic (ROC) Analysis on Peak GH (Growth Hormon) Concentrations — 2.36; 17.71 ng/mL
Phase 3 N=495 A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.
Bipolar I Disorder
Primary: Number of Subjects With at Least One Adverse Event (AE) and Adverse Drug Reaction (ADR) — 352; 169 Participants
Phase 3 N=46 YH1 in Poorly Controlled Type 2 Diabetes
Type 2 Diabetes
Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change
Phase 3 N=889 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3
Influenza, Human
Primary: Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE) — 1; 0; 1; 0 Participants
Phase 3 N=235 A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
Diphtheria · Tetanus · Pertussis
Primary: Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T), Post Primary Vaccination — 176; 176 Participants
Phase 3 N=214 A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
Prostate Neoplasms
Primary: DB Phase: Time to Prostate-Specific Antigen Progression (PSA) — 84.00; 169.00 Days — p=0.0002
Phase 3 N=54 Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression
Bipolar Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.64; -5.32 units on a scale
Phase 3 N=68 Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration
Pantothenate Kinase-Associated Neurodegeneration
Primary: Number of Participants With Adverse Events — 22; 42; 12; 14 Participants
Phase 3 N=924 A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea
Rosacea
Primary: Percent Change From Baseline in the Inflammatory Lesions (Papules and Pustules) Counts at Week 12 — -64.28; -65.15; -57.84 percent change — p=<.0001
Phase 3 N=422 Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis
Actinic Keratosis
Primary: Percentage of Participants With Treatment Success (Complete Clearance) at Week 6 — 33.9; 33.9; 3.3 percentage of participants — p=<0.0001
Phase 3 N=592 Study Assessing Double-masked Uveitis Treatment
Uveitis; Posterior, Disorder
Primary: The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5 — 28; 44; 27 Participants